A ALNY

Alnylam Pharmaceuticals Inc

BIOTECHNOLOGY · HEALTHCARE

Alnylam Pharmaceuticals, Inc. is a leading biopharmaceutical company based in Cambridge, Massachusetts, specializing in RNA interference (RNAi) therapeutics to address genetic diseases. The company has successfully launched its first commercial product and boasts a diverse pipeline of innovative RNA...

$220.33

+7.21% (+$14.81)

Volume 3.32M

52W High $495.55

52W Low $197.81

Market Cap $38.27B

← Back to Calendar Compare with Others →

Next Earnings Report

Last Reported

Jul 30, 2026 Missed

Actual: $1.21 vs. Consensus: $1.44

Price Chart

EPS History: Consensus vs Actual

Last 12 quarters

Price Movement Around Earnings

Q2 2026 Jul 30, 2026

1-Day: +0.02%

Q1 2026 Apr 30, 2026

1-Day: -4.32%

5-Day: -2.71%

Q1 2026 Mar 31, 2026

1-Day: -0.65%

Q4 2025 Feb 12, 2026

1-Day: +1.92%

5-Day: +7.82%

Revenue & Financial Performance

Quarter	Revenue	YoY Growth	Gross Margin	Op Margin	Net Income
Q2'26	$1.29B	+66.9%	76.9%	17.9%	$164.5M
Q1'26	$1.17B	+96.4%	81.9%	23.0%	$206.0M
Q4'25	$1.10B	+85.0%	75.6%	12.0%	$186.4M
Q3'25	$1.25B	+149.4%	84.2%	29.5%	$251.1M
Q2'25	$773.7M	+17.3%	81.5%	-2.1%	-$66.3M
Q1'25	$594.2M	+20.2%	88.0%	3.0%	-$57.5M
Q4'24	$593.2M	+34.9%	82.7%	-17.7%	-$83.8M
Q3'24	$500.9M	-33.3%	82.9%	-15.4%	-$111.6M

Historical Earnings

Last 12 quarters

Quarter	Date	Consensus	Whisper	Actual EPS	Surprise %	Result
Q2 2026	Jul 30, 2026	$1.44	$1.64	$1.21	-15.97%	Missed
Q1 2026	Apr 30, 2026	$1.47	$1.69	$1.99	+35.37%	Beat
Q1 2026	Mar 31, 2026	$1.47	$1.71	$1.99	+35.30%	Beat
Q4 2025	Feb 12, 2026	$1.50	$1.73	$1.25	-16.67%	Missed
Q3 2025	Oct 30, 2025	$1.75	$1.66	$2.90	+65.71%	Beat
Q2 2025	Jul 31, 2025	$0.15	-$0.70	$0.32	--	Beat
Q1 2025	May 1, 2025	-$0.37	-$0.37	-$0.01	+97.30%	Beat
Q4 2024	Feb 13, 2025	-$0.14	-$0.14	$0.06	--	Beat
Q3 2024	Oct 31, 2024	-$0.39	-$0.39	-$0.50	-28.21%	Missed
Q2 2024	Aug 1, 2024	-$0.69	-$1.08	$0.56	--	Beat
Q1 2024	May 2, 2024	-$0.63	-$1.18	-$0.16	+74.60%	Beat
Q4 2023	Feb 15, 2024	-$0.77	-$1.32	-$0.77	+0.00%	Beat